Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol

Asthma Clinical Trial

Official title:

A Dose Response and PharmacoDynamic Study of Levalbuterol and Racemic Albuterol HFA MDI in Subjects Twelve Years of Age and Older With Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00685425
• Other study ID #: 051-308
• Status: Completed
• Phase: Phase 3
• First received: May 23, 2008
• Last updated: February 21, 2012
• Start date: October 2002
• Est. completion date: March 2003

Study information

• Verified date: February 2012
• Source: Sunovion
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate, using an exercise challenge approach, the dose response of levalbuterol HFA MDI in adolescent and adult subjects with asthma

Description:

A randomized, modified-blind, active controlled, multicenter, parallel treatment, 3x3 dose level crossover study evaluating the dose response of levalbuterol in subjects 12 years of age and older with exercise induced bronchoconstriction. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: March 2003
• Est. primary completion date: March 2003
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Subject, male or female, must be at least 12 years of age at the time of consent.

• Female subjects 12-60 years of age must have a negative serum pregnancy test.

• Women of child bearing potential must be using an acceptable method of birth control throughout the study.

• Subject must have a documented diagnosis of asthma for a minimum of 6 months prior to study start

• Subject must be in good health with the exception of their reversible airways disease and not suffering from any chronic condition that might affect their respiratory function.

• Subject must have a chest X-ray for the study or within 12 months prior to randomization.

• Subject must be able to complete the diary cards and medical event calendars reliably on a daily basis and understand dosing instructions. Any minor subject who is not able to do this must have a parent/legal guardian who can assist them during the study with these activities.

Exclusion Criteria:

• Female subject who is pregnant or lactating.

• Subject who has participated in an investigational drug study within 30 days of study start, or who is currently participating in another clinical trial.

• Subject whose schedule prevents him or her from starting study visits before 12 PM.

• Subject who is unwilling or physically unable to perform the exercise challenges as described in the protocol.

• Subject who has travel commitments during the study that would interfere with trial measurements or compliance or both.

• Subject who has a history of hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial.

• Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations.

• Subject using any prescription drug with which albuterol sulfate administration is contraindicated.

• Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start.

• Subject with a history of cancer (exception: basal cell carcinoma in remission).

• Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders that currently are not well controlled by medication or that may interfere with the successful completion of this protocol.

• Subject with a history of substance abuse or drug abuse within 12 months preceding study start. Urine drug test must be negative at study start.

• Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start.

• Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis.

• Subject who has suffered from a clinically significant upper or lower respiratory tract infection in the 3 weeks prior to study start.

• Subjects with unstable asthma; or who have had a change in asthma therapy; or a visit to the Emergency Department or hospital for worsening asthma within 4 weeks.

• Subject who is a staff member or relative of a staff member.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Asthma
• Bronchoconstriction

Intervention

Drug:
• Levalbuterol HFA MDI
levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Arm #A Xopenex HFA MDI
• Racemic Albuterol
racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Arm #B Proventil HFA MDI

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sunovion

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	FEV1 AUC 0-60 (% decrease from post-dose/pre-challenge FEV1)		Days -7, 0, 5, 10, 15	No
Secondary	Maximum percent decrease in FEV1 from visit post-dose/pre-challenge FEV1		Days -7, 0, 5, 10, 15	No
Secondary	Minimum percent change in FEV1 from visit pre-dose FEV1.		Days -7, 0, 5, 10, 15	No
Secondary	time to recovery (min), Protected/Unprotected Subjects Counts		Days -7, 0, 5, 10, 15	No
Secondary	FVC AUC 0-60 (% decrease from post-dose/pre-challenge FEV1).		Days -7, 0, 5, 10, 15	No
Secondary	Maximum percent decrease in FVC from visit post-dose/pre-challenge FVC,		Days -7, 0, 5, 10, 15	No
Secondary	Minimum percent change in FVC for pre-dose FVC,		Days -7, 0, 5, 10, 15	No
Secondary	FEF25-75% AUC 0-60 (% decrease from post-dose/pre-challenge FEV1),		Days -7, 0, 5, 10, 15	No
Secondary	Maximum percent decrease in FEF25-75% from visit post-dose/pre-challenge FEF25-75%		Days -7, 0, 5, 10, 15	No
Secondary	Minimum percent change in FEF25%-75% from visit pre-dose FEF25-75%.		Days -7, 0, 5, 10, 15	No